Thierry Verbinnen

<i>In Vitro</i> Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

Oliver Lenz, Thierry Verbinnen, Tse‐I Lin et al. · Antimicrobial Agents and Chemotherapy · 2010 · 211 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

Tse‐I Lin, Oliver Lenz, Gregory Fanning et al. · Antimicrobial Agents and Chemotherapy · 2009 · 190 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies

Oliver Lenz, Thierry Verbinnen, Bart Fevery et al. · Journal of Hepatology · 2014 · 132 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection

Fabien Zoulim, Oliver Lenz, Joris Vandenbossche et al. · Gastroenterology · 2020 · 116 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Tracking the Evolution of Multiple<i>In Vitro</i>Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing

Thierry Verbinnen, Herwig Van Marck, Ina Vandenbroucke et al. · Journal of Virology · 2010 · 67 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17